Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3aa46a67ff055c5f1ccf1dca4da739ac |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-551 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4166 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-635 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-551 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4166 |
filingDate |
2019-02-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate |
2019-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2019215488-A1 |
titleOfInvention |
Formulations and methods for the treatment of cancers |
abstract |
A formulation for treating cancer comprising an androgen receptor signaling inhibitor and a B-cell lymphoma 2 inhibitor, which may further comprising a Bromodomain and Extra Terminal protein inhibitor or a phosphoinositide 3-kinase inhibitor. |
priorityDate |
2018-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |